These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36963335)

  • 41. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set.
    Liu H; Tang T
    Front Oncol; 2022; 12():952290. PubMed ID: 36276096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
    Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
    Front Immunol; 2022; 13():974034. PubMed ID: 36203594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma.
    Long S; Wang Y; Chen Y; Fang T; Yao Y; Fu K
    Biol Direct; 2022 Oct; 17(1):28. PubMed ID: 36209249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
    Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
    J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrative analysis of LAG3 immune signature and identification of a LAG3-related genes prognostic signature in kidney renal clear cell carcinoma.
    Li J; Liu C; Su H; Dong H; Wang Z; Wang Y; Zhao P; Zhang C; Zhao Y; Ma X
    Aging (Albany NY); 2024 Jan; 16(3):2161-2180. PubMed ID: 38277212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinoma.
    Hou S; Gu T; Shi Y; Huang Y; Yao J; Luo P; Cao M; Zhang J; Lin A; Zhu W
    Cancer Biomark; 2023; 38(4):489-504. PubMed ID: 38043008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An
    Fu S; Gong B; Ding Y; Zhuang C; Chen Q; Wang S; Li Z; Ma M; Liu Y; Zhang Z; Sun T
    Comb Chem High Throughput Screen; 2022; 25(13):2278-2294. PubMed ID: 35293292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma.
    Khadirnaikar S; Kumar P; Pandi SN; Malik R; Dhanasekaran SM; Shukla SK
    Mol Carcinog; 2019 Apr; 58(4):544-553. PubMed ID: 30520148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Construction of a Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response in Kidney Renal Clear Cell Carcinoma.
    Zhang Y; Zhuang T; Xin Z; Sun C; Li D; Ma N; Wang X; Wang X
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
    Han G; Zhao W; Song X; Kwok-Shing Ng P; Karam JA; Jonasch E; Mills GB; Zhao Z; Ding Z; Jia P
    BMC Genomics; 2017 Oct; 18(Suppl 6):678. PubMed ID: 28984208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cuproptosis identifies respiratory subtype of renal cancer that confers favorable prognosis.
    Li K; Tan L; Li Y; Lyu Y; Zheng X; Jiang H; Zhang X; Wen H; Feng C
    Apoptosis; 2022 Dec; 27(11-12):1004-1014. PubMed ID: 36103026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinicopathological and Prognostic Value of Necroptosis-Associated lncRNA Model in Patients with Kidney Renal Clear Cell Carcinoma.
    Gu J; He Z; Huang Y; Luan T; Chen Z; Wang J; Ding M
    Dis Markers; 2022; 2022():5204831. PubMed ID: 35664432
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma.
    Jiang S; Dong Y; Wang J; Zhang X; Liu W; Wei Y; Zhou H; Shen L; Yang J; Zhu Q
    Front Immunol; 2023; 14():1207061. PubMed ID: 37662929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.
    Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S
    Front Immunol; 2022; 13():945516. PubMed ID: 36248857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma.
    Wang H; Yang Z; He X; Guo F; Sun H; Xu S; Xu C; Wang Z; Wen H; Teng Z; Wang Y; Han Z
    BMC Cancer; 2023 Aug; 23(1):804. PubMed ID: 37641032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construction and validation of risk model of EMT-related prognostic genes for kidney renal clear cell carcinoma.
    Wu LL; Yuan SF; Lin QY; Chen GM; Zhang W; Zheng WE; Lin HL
    J Gene Med; 2023 Nov; 25(11):e3549. PubMed ID: 37271571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
    Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
    Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.